BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34120846)

  • 1. Discordance Between Immunohistochemistry and In Situ Hybridization to Detect HER2 Overexpression/Gene Amplification in Breast Cancer in the Modern Age: A Single Institution Experience and Pooled Literature Review Study.
    Memon R; Prieto Granada CN; Harada S; Winokur T; Reddy V; Kahn AG; Siegal GP; Wei S
    Clin Breast Cancer; 2022 Jan; 22(1):e123-e133. PubMed ID: 34120846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
    Lim SJ; Cantillep A; Carpenter PM
    Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The assessment of HER2 status in breast cancer: the past, the present, and the future.
    Nitta H; Kelly BD; Allred C; Jewell S; Banks P; Dennis E; Grogan TM
    Pathol Int; 2016 Jun; 66(6):313-24. PubMed ID: 27061008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
    van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
    Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program.
    Bilous M; Morey AL; Armes JE; Bell R; Button PH; Cummings MC; Fox SB; Francis GD; Waite B; McCue G; Raymond WA; Robbins PD; Farshid G
    Breast Cancer Res Treat; 2012 Jul; 134(2):617-24. PubMed ID: 22678156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of HER2 Immunohistochemistry-Negative, FISH-Amplified Breast Cancers and Their Response to Anti-HER2 Neoadjuvant Chemotherapy.
    Gibbons-Fideler IS; Nitta H; Murillo A; Tozbikian G; Banks P; Parwani AV; Li Z
    Am J Clin Pathol; 2019 Jan; 151(2):176-184. PubMed ID: 30339245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
    Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
    Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of breast cancer HER-2 receptor testing with immunohistochemistry and in situ hybridization.
    Shanmugalingam A; Hitos K; Pathmanathan N; Edirimmane S; Hughes TM; Ngui NK
    Breast Cancer Res Treat; 2023 Feb; 198(1):143-148. PubMed ID: 36604351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
    Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
    Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The spectrum of HER2 expression in breast cancer: linking immunohistochemistry quantification with in situ hybridization assay.
    Polónia A; Canelas C; Caramelo A
    Virchows Arch; 2022 Jun; 480(6):1171-1179. PubMed ID: 35137279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of 2018 ASCO-CAP HER2 testing guidelines on breast cancer HER2 results. An audit of 2132 consecutive cases evaluated by immunohistochemistry and in situ hybridization.
    Farshid G; Dhatrak D; Gilhotra A; Koszyca B; Nolan J
    Mod Pathol; 2020 Sep; 33(9):1783-1790. PubMed ID: 32366941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.
    Nitta H; Kelly BD; Padilla M; Wick N; Brunhoeber P; Bai I; Singh S; Ranger-Moore J; Bieniarz C; Tsuda H; Grogan TM
    Diagn Pathol; 2012 May; 7():60. PubMed ID: 22647525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
    Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
    Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer.
    Stocker A; Trojan A; Elfgen C; Hilbers ML; Moskovszky L; Varga Z
    Breast Cancer Res Treat; 2020 Sep; 183(2):311-319. PubMed ID: 32638236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "HER2 immunohistochemistry inter-observer reproducibility in 205 cases of invasive breast carcinoma additionally tested by ISH" Answer to the statistical issue to avoid misinterpretation.
    Casterá Redal C; Bernet Vegué L
    Ann Diagn Pathol; 2020 Oct; 48():151566. PubMed ID: 32763505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study.
    Hanna WM; Barnes PJ; Chang MC; Gilks CB; Magliocco AM; Rees H; Quenneville L; Robertson SJ; SenGupta SK; Nofech-Mozes S
    J Clin Oncol; 2014 Dec; 32(35):3967-73. PubMed ID: 25385731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What to expect from the 2018 ASCO/CAP HER2 guideline in the reflex in situ hybridization test of immunohistochemically equivocal 2+ cases?
    Curado M; Caramelo AS; Eloy C; Polónia A
    Virchows Arch; 2019 Sep; 475(3):303-311. PubMed ID: 30953146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation.
    Koopman T; van der Vegt B; Dijkstra M; Bart J; Duiker E; Wisman GBA; de Bock GH; Hollema H
    Histopathology; 2018 Nov; 73(5):852-863. PubMed ID: 29989198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ hybridization DNA probe cocktail assay performed on cell blocks to immunohistochemisty and fluorescence in situ hybridization performed on histologic specimens.
    Hartman AK; Gorman BK; Chakraborty S; Mody DR; Schwartz MR
    Arch Pathol Lab Med; 2014 Apr; 138(4):553-8. PubMed ID: 24678687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 immunohistochemistry inter-observer reproducibility in 205 cases of invasive breast carcinoma additionally tested by ISH.
    Casterá C; Bernet L
    Ann Diagn Pathol; 2020 Apr; 45():151451. PubMed ID: 31955049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.